Biophytis Earlier Announced Successful Capital Raise Of €2.3M

Benzinga · 05/11/2023 07:08

/ Biophytis SA (NasdaqCM:BPTS)(PARIS:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, is today announcing it has successfully completed its fundraising round for a total amount of €2.3M through capital increases with cancellation of the shareholders' preferential subscription rights to the benefit of professional investors up to €1.9M on the one hand, and to the benefit of individual investors via the PrimaryBid platform up to €0.4M on the other hand.